Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

2004/04/09 by Kwang Kon Koh, Jeong Yeal Ahn, Seung Hwan Han +6 · 8 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cholesterol #Diabetes, Cardiovascular Risks, and Lipoproteins #Endocrinology #Fenofibrate #Fibrinogen #Hypertriglyceridemia #Internal medicine #Lipoprotein #Lipoprotein(a) #Lipoproteins and Cardiovascular Health #Medicine #Peroxisome Proliferator-Activated Receptors #Plasminogen activator #Triglyceride

paper · doi:10.1016/j.atherosclerosis.2004.01.033

openalex publication_date 2004/04/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26

Cited by

• Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. [europepmc]
• The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. [europepmc]
• Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. [europepmc]
• Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study. [europepmc]
• Genetic risk scores associated with baseline lipoprotein subfraction concentrations do not associate with their responses to fenofibrate. [europepmc]
• Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study. [europepmc]
• Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). [europepmc]
• Hepatic-vascular crosstalk via GRK2: fenofibrate improves endothelial function by restoring lipid metabolism and NO signaling in obese mice. [europepmc]